| 1 |
32869328 | An In Vitro and In Vivo Evaluation of the Effect of Relacorilant on the Activity of Cytochrome P450 Drug Metabolizing Enzymes. | 2021 Feb |
1 |
| 2 |
32050158 | An improved cytochrome P450 phenotyping cocktail with a simplified and highly sensitive UHPLC-MS/MS assay in human plasma. | 2020 Mar 1 |
1 |
| 3 |
30992242 | Influences of cytochrome b5 expression and its genetic variant on the activity of CYP2C9, CYP2C19 and CYP3A4. | 2019 Jun |
1 |
| 4 |
27934636 | Impact of Probe Substrate Selection on Cytochrome P450 Reaction Phenotyping Using the Relative Activity Factor. | 2017 Feb |
1 |
| 5 |
28073119 | In Vitro Inhibition of Human CYP450s 1A2, 2C9, 3A4/5, 2D6 and 2E1 by Grandisin. | 2017 May |
1 |
| 6 |
23153057 | Assessment of cytochrome P450 (1A2, 2B6, 2C9 and 3A4) induction in cryopreserved human hepatocytes cultured in 48-well plates using the cocktail strategy. | 2013 Apr |
1 |
| 7 |
22896727 | Impact of organic solvents on cytochrome P450 probe reactions: filling the gap with (S)-Warfarin and midazolam hydroxylation. | 2012 Nov |
1 |
| 8 |
20501911 | Metabolite formation kinetics and intrinsic clearance of phenacetin, tolbutamide, alprazolam, and midazolam in adenoviral cytochrome P450-transfected HepG2 cells and comparison with hepatocytes and in vivo. | 2010 Sep |
1 |
| 9 |
16501008 | Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. | 2006 May |
1 |
| 10 |
11573629 | Cytochrome P4502B6 and 2C9 do not metabolize midazolam: kinetic analysis and inhibition study with monoclonal antibodies. | 2001 Apr |
1 |
| 11 |
10348802 | Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1. | 1999 Jun |
1 |
| 12 |
9867310 | In vivo age-related changes in hepatic drug-oxidizing capacity in humans. | 1998 Aug |
1 |